Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing its mission to revolutionize cardiovascular disease prevention and early detection through precision medicine, as outlined by CEO and Co-Founder Dr. Meesha Dogan in a recent appearance on The BioMedWire Podcast. The company leverages epigenetics, genetics, and artificial intelligence to develop personalized clinical tests aimed at making cardiovascular care more accessible and precise.
During the podcast, Dr. Dogan highlighted the company’s strategic expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs. This move positions Cardio Diagnostics to tap into one of the world’s largest healthcare markets, addressing the growing burden of cardiovascular disease in India. The partnerships are expected to facilitate the distribution and adoption of the company’s AI-driven diagnostic tests in the region.
In addition to international growth, Dr. Dogan provided an update on the company’s progress through the Medicare reimbursement process. She noted that the CPT coding and payment steps have been completed, a critical milestone for ensuring that Cardio Diagnostics’ tests are covered by Medicare. However, the coverage determination, which will define the specific indications and patient populations eligible for reimbursement, is still underway. This step is crucial for the commercial viability of the tests in the U.S. market.
The company’s core technology, an AI-driven Integrated Genetic-Epigenetic Engine, underpins its suite of diagnostic tests. By analyzing genetic and epigenetic markers, the technology aims to identify individuals at risk for cardiovascular events before symptoms arise, potentially reducing the incidence of heart attacks and strokes. The precision medicine approach also allows for tailored treatment plans, improving patient outcomes.
Cardio Diagnostics’ focus on innovation and accessibility aligns with broader trends in healthcare toward personalized medicine. The expansion into India, a country with a high prevalence of cardiovascular disease, could have significant public health implications. If successful, the company’s tests could enable early intervention in populations that currently lack adequate screening options.
Dr. Dogan’s appearance on the podcast underscores the company’s commitment to transparency and investor communication. The full interview is available for those seeking more details on Cardio Diagnostics’ strategy and technology. For more information about the company and its latest news, visit its newsroom at https://ibn.fm/CDIO.
The press release containing these details can be accessed at https://ibn.fm/0VjIz. As with any forward-looking statements, the company cautions that actual results may differ materially from those projected due to various risks and uncertainties, as detailed in its filings with the SEC.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Cardio Diagnostics CEO Details Growth Strategy and India Expansion on BioMedWire Podcast.